The estimated Net Worth of Life Sciences Viii, L.P.Top... is at least 3.1 百万$ dollars as of 9 January 2020. Life Top owns over 50,000 units of Entasis Therapeutics Inc stock worth over 2,846,897$ and over the last 5 years Life sold ETTX stock worth over 250,000$.
Sign up
Life Top ETTX stock SEC Form 4 insiders trading
Life has made over 1 trades of the Entasis Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Life sold 50,000 units of ETTX stock worth 250,000$ on 9 January 2020.
The largest trade Life's ever made was selling 50,000 units of Entasis Therapeutics Inc stock on 9 January 2020 worth over 250,000$. On average, Life trades about 50,000 units every 0 days since 2020. As of 9 January 2020 Life still owns at least 1,299,953 units of Entasis Therapeutics Inc stock.
You can see the complete history of Life Top stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Entasis Therapeutics Inc
Over the last 6 years, insiders at Entasis Therapeutics Inc have traded over 348,925$ worth of Entasis Therapeutics Inc stock and bought 50,891,639 units worth 170,673,776$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Inc.Innoviva Strategic Oppo...、Holdings A/S Novo. On average, Entasis Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of 4,855,580$. The most recent stock trade was executed by Inc.Innoviva Strategic Oppo... on 8 July 2022, trading 19,270,476 units of ETTX stock currently worth 42,395,047$.
What does Entasis Therapeutics Inc do?
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
What does Entasis Therapeutics Inc's logo look like?
Complete history of Life Top stock trades at Entasis Therapeutics Inc
Entasis Therapeutics Inc executives and stock owners
Entasis Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Dr. Manoussos Perros,
Pres, CEO & Director -
Dr. David Altarac,
Chief Medical Officer -
Dr. John Patrick Mueller Ph.D.,
Chief Devel. Officer -
Kristie Wagner,
Interim VP & Interim Principal Financial and Accounting Officer -
Anna Diaz Triola MBA,
Chief Commercial Officer -
Dr. Matthew Ronsheim Ph.D.,
Chief Pharmaceutical Sciences & Manufacturing Officer -
Colleen Tucker,
Head of HR -
Elizabeth M. Keiley,
Gen. Counsel -
Dr. Ruben Tommasi,
Chief Scientific Officer -
Dr. Michael J. Gutch MBA, Ph.D.,
CFO, Chief Bus. Officer & Sec. -
Life Sciences Viii, L.P.Top...,
-
Anna Diaz Triola,
Chief Commercial Officer -
Inc. Innoviva,,
10% owner -
Venture Partners Ix, L.P.So...,
-
Lifesciences Iii, L.P.Claru...,
-
Group Holdings (Sbs) Adviso...,
-
Ruben Tommasi,
Chief Scientific Officer -
Robin Isaacs,
Chief Medical Officer -
Nicholas Galakatos,
Director -
James N Topper,
Director -
Bio Venture Partners Fund I...,
-
Life Sciences Viii, L.P.Fhm...,
-
Plcastrazeneca Ab Astrazeneca,
-
Holdings A/S Novo,
10% owner -
John Patrick Mueller,
Chief Development Officer -
Heather Preston,
Director -
Gregory Norden,
Director -
David C Hastings,
Director -
Heather A. Berger,
Director -
Howard Mayer,
Director -
David D. Meek,
Director -
David Altarac,
Chief Medical Officer -
Eric Wilson Kimble,
Chief Commercial Officer -
Elizabeth M Keiley,
General Counsel -
Kristie Ann Wagner,
VP, Principal Fin & Acct Off -
Inc.Innoviva Strategic Oppo...,
-
Manoussos Perros,
President and CEO -
Michael Gutch,
See Remarks -
Matthew Ronsheim,
Chief of Pharma Sciences & MFG